1 February 2012
Acrux (ASX: ACR) announced today that Swissmedic, the Swiss agency for therapeutic products, has granted a marketing authorisation in Switzerland for Ellavie™, Acrux’s estradiol spray for treating menopause symptoms.
Acrux’s estradiol spray is approved for marketing in the United States and Sweden, with marketing applications under review by regulatory authorities in South Korea and South Africa. The approval in Sweden enables Acrux to seek marketing approvals in other European countries under a Mutual Recognition Procedure.
Acrux is currently engaged in commercial discussions with potential marketing and manufacturing partners for the estradiol spray in the European Union and in Eastern Europe.
“We are delighted that our marketing partner in Switzerland has achieved approval for Ellavie. We expect to advance the commercialisation of our estradiol spray product in the broader European market through further partnerships.” said Acrux CEO Richard Treagus.
The estrogen therapy market outside the USA is valued at US$360 million per annum.
In Europe, transdermal therapies (skin patches and gels) account for approximately half of the estrogen therapy market.